ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by research analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research note issued on Monday, PriceTargets.com reports.
A number of other research analysts have also issued reports on the company. Raymond James raised ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price on the stock in a report on Friday, August 12th. HC Wainwright dropped their price target on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $5.00.
Get
ProQR Therapeutics alerts:
ProQR Therapeutics Price Performance
Shares of NASDAQ PRQR opened at $0.87 on Monday. ProQR Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $9.09. The firm's 50-day simple moving average is $0.80 and its 200 day simple moving average is $1.14. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.43. The stock has a market cap of $62.02 million, a P/E ratio of -0.87 and a beta of 0.80.
Hedge Funds Weigh In On ProQR Therapeutics
Several large investors have recently made changes to their positions in the company. Monaco Asset Management SAM acquired a new position in ProQR Therapeutics in the first quarter valued at about $82,000. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 10.0% in the first quarter. Privium Fund Management B.V. now owns 5,244,446 shares of the biopharmaceutical company's stock worth $4,747,000 after acquiring an additional 478,787 shares in the last quarter. Prosight Management LP increased its holdings in shares of ProQR Therapeutics by 68.0% in the first quarter. Prosight Management LP now owns 599,288 shares of the biopharmaceutical company's stock worth $542,000 after acquiring an additional 242,671 shares in the last quarter. M28 Capital Management LP bought a new stake in shares of ProQR Therapeutics in the first quarter worth about $907,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock worth $31,346,000 after acquiring an additional 481,325 shares in the last quarter.
ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
